CAS: 1631754-41-0; 2-(((2R,6S,9S,11R,12R,14As,15S,16S,20S,23S,25As)-23-((1S,2S)-1,2-Dihydroxy-2-(4-Hydroxyphenyl)Ethyl)-2,11,15-Trihydroxy-6,20-Bis((R)-1-Hydroxyethyl)-16-Methyl-5,8,14,19,22,25-Hexaoxo-9-(4''-(Pentyloxy)-[1,1':4',1''-Terphenyl]-4-Carboxamido)Tetracosahydro-1H-Dipyrrolo[2,1-C:2',1'-L][1,4,7,10,13,16]Hexaazacyclohenicosin-12-yl)Oxy)-N,N,N-Trimethylethan-1-Aminium Acetate
该化合物是一种合成抗反爆剂,能对广泛的真菌病原体进行强有力的活动,它展示了快速的真菌杀菌活动,为各种真菌感染提供了有效的治疗.它独特的行动机制针对真菌细胞墙,提供了一种新的治疗选择,对其他抗菌剂的跨抗性最小. Rezafungin ceate(Rezafungin apate)展示了高效力和有利的安全特征,使它成为防治真菌疾病的天体化机构的宝贵补充.
- 英文名称2-(((2R,6S,9S,11R,12R,14As,15S,16S,20S,23S,25As)-23-((1S,2S)-1,2-Dihydroxy-2-(4-Hydroxyphenyl)Ethyl)-2,11,15-Trihydroxy-6,20-Bis((R)-1-Hydroxyethyl)-16-Methyl-5,8,14,19,22,25-Hexaoxo-9-(4''-(Pentyloxy)-[1,1':4',1''-Terphenyl]-4-Carboxamido)Tetracosahydro-1H-Dipyrrolo[2,1-C:2',1'-L][1,4,7,10,13,16]Hexaazacyclohenicosin-12-yl)Oxy)-N,N,N-Trimethylethan-1-Aminium Acetate
- 中文名称雷扎芬净乙酸酯
- IUPAC名称2-(((2R,6S,9S,11R,12R,14aS,15S,16S,20S,23S,25aS)-23-((1S,2S)-1,2-dihydroxy-2-(4-hydroxyphenyl)ethyl)-2,11,15-trihydroxy-6,20-bis((R)-1-hydroxyethyl)-16-methyl-5,8,14,19,22,25-hexaoxo-9-(4''-(pentyloxy)-[1,1':4',1''-terphenyl]-4-carboxamido)tetracosahydro-1H-dipyrrolo[2,1-c:2',1'-l][1,4,7,10,13,16]hexaazacyclohenicosin-12-yl)oxy)-N,N,N-trimethylethan-1-aminium acetate
- 其它别名Acetato De Rezafungina; Mxmwjapnuikpgf-Mlauikivsa-N; 2-[[(3S,9S,11R,15S,18S,20R,21R,24S,25S,26S)-6-[(1S,2S)-1,2-Dihydroxy-2-(4-Hydroxyphenyl)Ethyl]-11,20,25-Trihydroxy-3,15-Bis[(1R)-1-Hydroxyethyl]-26-Methyl-2,5,8,14,17,23-Hexaoxo-18-[[4-[4-(4-Pentoxyph
- CAS编号1631754-41-0
- MFCD编号:MFCD32899863
- FDA UNII编号:W1U1TMN677
- 分子式:C65H88N8O19分子量:1285.46
- 产品CID: 827332
- 同类组份化合物CAS1631754-41-0 (acetate)1396640-59-7 (cation)1396640-60-0 (TFA)Rezafungin chloride
物理性质
MSDS等安全信息
合成工艺路线路线简述
海关参考信息
- 2902600000-乙苯
2905122000-异丙醇
2905310000-1,2-乙二醇
2905320000-1,2-丙二醇 - 💡 提示：海关信息按照顺序优先匹配，如需确认的海关信息，请参考相关资料。
- 详情请参考：📖 海关编码查询和海关进出口税则
供应商参考报价(招募中)
品牌试剂参考报价(招募中)
📌 第三方产品分析报告
主要参考文献
1: Alsowaida YS, Alamer A, Thabit AK, Almulhim AS, Aleissa MM, Kalbasi A, Eljaaly K, Almangour TA, Erstad BL. Echinocandin exposures in obese patients: A scoping review and clinical perspectives. Am J Health Syst Pharm. 2023 Jan
21:zxad021. doi: 10.1093/ajhp/zxad021. Epub ahead of print. 30(4):9164-9183. doi: 10.1007/s11356-022-24032-2. Epub 2022 Dec 1.
3: Thompson GR 3rd, Soriano A, Cornely OA, Kullberg BJ, Kollef M, Vazquez J, Honore PM, Bassetti M, Pullman J, Chayakulkeeree M, Poromanski I, Dignani C, Das AF, Sandison T, Pappas PG; ReSTORE trial investigators. Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial. Lancet. 2023 Jan 7;401(10370):49-59. doi: 10.1016/S0140-6736(22)02324-8. Epub 2022 Nov 25. 401(10370):3-5. doi: 10.1016/S0140-6736(22)02371-6. Epub 2022 Nov 25. 8(11):1144. doi: 10.3390/jof8111144.
📝 需求与反馈
尽可能描述清楚需求与问题信息
